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Abstract
Introduction: b2-microglobulin (b2m) is required for the surface expression of MHC class I and class I-like proteins
such as CD1d, Qa1 and neonatal Fc receptor (FcRn), all of which may impact the development of autoimmunity.
Since CD1d is known to bind and present phospholipid antigens to T cells, we asked if the deficiency of b2m or
CD1d will impact the development of anti-phospholipid antibodies as compared to other aspects of lupus
autoimmunity.
Methods: We introgressed the b2m-null genotype onto the NZB and NZW backgrounds for 12 to 14 generations
to generate genetically lupus-susceptible (NZB/NZW)F1 (BWF1) mice that are b2m-deficient (b2m°). Circulating
immunoglobulins (Ig), rheumatoid factor (RF), anti-DNA and anti-cardiolipin (anti-CL) antibodies, and renal disease
were analyzed in these and CD1d-deficient (CD1d°) BWF1 mice that we had previously generated.
Results: Whereas b2m° BWF1 mice had reduced serum IgG, they had increased mortality, nephritis, serum IgG
anti-DNA antibody and RF as compared to heterozygous and wild-type littermates. These effects were
recapitulated in CD1d° BWF1 mice, except that they also had increased serum IgG as compared to control
littermates. Intriguingly, both b2m° and CD1d° mice had lower serum anti-CL antibody levels than in control
littermates. Such CD1d dependence of anti-CL antibody production is not mediated by CD1d/glycolipid-reactive
iNKT cells, as these cells reduced the production of RF and anti-DNA antibodies but had no effect on anti-CL
antibodies.
Conclusions: We report a novel dichotomous role of b2m and CD1d, whereby these molecules differently regulate
autoimmunity against phospholipid versus non-phospholipid autoantigens.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by uncontrolled production of
autoantibodies against a variety of antigens such as
nucleic acids and phospholipids, hypergammaglobuline-
mia and multi-organ inflammation [1]. Diverse sets of
T-cells - CD4+, TCRab+CD4-CD8-, or gδ+ T-cells - can
promote autoantibody production [2-4]. The emergence
of such autoreactive T helper cells in lupus is accompa-
nied by impaired regulatory mechanisms, which include
CD8+, invariant natural killer T (NKT) and gδ+ T-cells
[4-9]. Elucidating the role of antigen presenting mole-
cules that present autoantigens to helper and regulatory
T-cells would facilitate our understanding of the etiol-
ogy and pathogenesis of lupus.
b2-microglobulin (b2m) is required for the expression
of cell surface molecules, including classical major histo-
compatibility complex (MHC) class I, CD1, Qa-1, and
FcRn (neonatal Fc receptor), and for the development of
CD8+, NKT, and CD3+CD4-CD8- T-cell subsets [10,11],
all of which may potentially impact the development of
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humoral autoimmunity. In fact, several studies have
used b2m-deficient (b2m°) mice to demonstrate a role
of b2m-dependent events in the development of lupus.
For example, b2m° NZB mice have reduced anti-
erythrocyte antibodies and hemolytic anemia [12], and
b2m° 129/J mice are resistant to an idiotype-induced
experimental SLE [13]. b2m° MRL-lpr/lpr mice also
exhibit decreases in anti-DNA antibody production,
hypergammaglobulinemia and lupus nephritis [14-16].
These protective effects of b2m deficiency have been
linked with the absence of FcRn [15], which is known to
inhibit immunoglobulin G (IgG) catabolism [17,18].
However, lupus dermatitis is aggravated in b2m° MRL-
lpr/lpr mice [16]. Mechanisms underlying such disparate
effects of b2m-deficiency on autoimmune disease remain
to be determined. Since b2m promotes the activation of
CD8+ and NKT cells via its association with MHC class I
and CD1d, respectively, b2m deficiency may aggravate
aspects of autoimmunity that are normally controlled by
such potentially regulatory T-cells [5-7].
CD1d can also bind phospholipid antigens [19,20] and
activate T-cells [21,22]. We reasoned that the absence
of such CD1d-restricted self-phospholipid-reactive
T-cells might result in the decreased production of
anti-phospholipid antibody in b2m° and CD1d° mice.
Here, we investigated the role of b2m on diverse aspects
of lupus - survival, nephritis, hypergammaglobulinemia,
rheumatoid factor (RF) and anti-DNA and anti-cardiolipin
(anti-CL) autoantibodies - using a genetically susceptible
animal model, namely NZB/NZW F1 (BWF1) mice that
develop T-cell-dependent, autoantibody-mediated disease
[23]. We show that b2m has distinct effects on diverse
aspects of lupus autoimmunity.
Material and methods
Mice
The b2m° 129xC57BL/6 mice were crossed onto the
NZB and NZW backgrounds (all from Jackson Labora-
tory, Bar Harbor, ME, USA) for 12 to 14 generations. At
each backcross the heterozygous (b2m+/-) mice were
identified by PCR using the neo [24] and b2m primers
(sense, 5’-TATCAGTCTCAGTGGGGGTG-3’; antisense,
5’-CTGAGCTCTGTTTTCGTCTG-3’). The N12 b2m+/-
NZB mice were crossed with N12 or N14 b2m+/- NZW
mice to establish b2m+/+, b2m+/-, and b2m-/- (b2m°)
BWF1 mice. The CD1d-/- (CD1d°) BWF1 mice were
generated by crossing N10 CD1d+/- NZB mice with N12
CD1d+/- NZW mice [8]. The b2m° and CD1d° pheno-
types were further confirmed by demonstrating absence
of CD1d by flow cytometry of peripheral blood lympho-
cytes using an anti-CD1d monoclonal antibody, 1B1
(PharMingen, San Diego, CA, USA). To confirm that
mice at the final backcross are indeed congenic, they
were screened using a battery of simple sequence repeat
markers (Jackson Laboratory), all of which discriminated
congenic strains from the 129/B6 donors. Va14Tg
BALB/c [25] and Ja18-/- (Ja18°) BALB/c [26] mice were
provided by Dr A Bendelac and Dr M Taniguchi,
respectively. BALB/c SCID mice were purchased from
Jackson Laboratory. All animal studies were performed
according to the approved guidelines of UCLA Animal
Research Committee.
Assessment of lupus disease
Survival, renal disease, and autoantibody and IgG levels
were assessed. Proteinuria was measured on a 0 to 4+
scale using a colorimetric assay strip (Albustix, Bayer,
Elkhart, IN, USA). Severe proteinuria was defined as
≥300 mg/dl on two consecutive examinations [6]. Kidney
sections were stained with H & E, periodic acid-Schiff
(PAS), and Masson’s trichrome, and scored in a blind
fashion [27,28]. In brief, the mean scores for individual
pathological features were summed to obtain the four
main scores, including glomerular activity score (GAS),
tubulointerstitial activity score (TIAS), chronic lesion
score (CLS), and vascular lesion score (VLS) (Additional
file 1, Table S1). These scores were converted into
indices by dividing them by the number of individual fea-
tures examined to obtain those scores. The indices thus
obtained were then averaged and summed to determine a
composite kidney biopsy index.
Detection of autoantibodies
IgG anti-dsDNA antibody was measured by ELISA, as
described [6], using serum samples diluted at 1:500 and
the secondary antibody, alkaline phosphatase (AP)-
conjugated goat-anti mouse IgG, at 1:1,000 dilution.
Rheumatoid factor (RF, anti-IgG2aa) was determined by
ELISA, as described [29], using serum samples diluted
at 1:250 and the secondary antibody, AP-conjugated
goat-anti mouse kappa at 1:1,000 dilution. Anti-CL anti-
bodies were detected as previously described [30]. In
brief, ELISA plates were coated with CL Ag (5 μg/ml,
≥97% TCL, Sigma, St. Louis, MO, USA) in 200-proof
ethyl alcohol (Daigger, Vernon Hills, IL, USA). Vehicle
(200-proof ethyl alcohol only) served as a control. Plates
were then dried under a hood for 30 minutes and blocked
with 1% BSA for 1 h at room temperature. Samples
(serum dilution 1:200 to 1:500) and standard were added
into plates for 2 h at room temperature. After washing,
plates were incubated with AP-conjugated goat-anti
mouse IgG (1:1,000) (Southern Biotechnology, Birming-
ham, AL, USA), developed with p-nitrophenyl phosphate
substrate (Sigma, MO, USA) and optical density (OD) was
determined at 405 nm using Multiskan (Thermo Labsys-
tems, Pittsburgh, PA, USA). Normal BALB/c serum was
used as a negative control and pooled serum from old
BWF1 or MRL-lpr mice was used as a reference positive
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control. Total serum Ig and its isotypes were measured by
a standard sandwich ELISA, using appropriate antibody
pairs (Southern Biotechnology Associates, Birmingham,
AL, USA), and serum samples diluted at 1:40,000 for total
IgG and 1:20,000 for IgM and IgG isotypes. The secondary
antibody, AP-conjugated goat-anti mouse IgG, IgM or IgG
isotypes, was diluted at 1:1000.
Reconstitution of SCID mice
BALB/c SCID mice were injected intraperitoneally (i.p.)
with 5 μg LPS and 6 μg aGalCer separately and trans-
ferred intravenously (i.v.) with purified B cells (1 to 3 ×
107) isolated from 10-month-old Ja18° mice. These
B-cell-reconstituted SCID mice were then transferred
i.v. with enriched T-cells (3 to 6 × 106) from donor 10-
week-old Va14Tg or control Ja18° mice. Four days after
the transfer, spleen cells harvested from these mice were
analyzed for T-cell receptor b (TCR b) and aGalCer/
CD1d-dimer+ cells to verify the reconstitution of SCID
mice with iNKT cells, as described previously [31]. As
expected, the recipients of Ja18 T cells had no iNKT
cells; and recipients of Va14Tg T cells had iNKT cells in
their spleen. Spleen cells from these mice were cultured
in complete medium without any further stimulation for
6 days. Culture supernatants were tested for IgG anti-
DNA and anti-CL antibodies.
Statistical analysis
Levels of antibodies and renal scores were compared
using Student’s t- or the Mann-Whitney U-test.
Frequencies of antibodies and proteinuria were com-
pared using two-sided Fisher’s exact test. Survival was
compared using a log-rank test.
Results
b2m deficiency in BWF1 mice accelerates lupus nephritis
and reduces survival
To investigate the role of b2m in the pathogenesis of
diverse manifestations of lupus, we generated N12 b2m+/-
NZB and N14 b2m+/- NZWmice and intercrossed them to
generate the final b2m° BWF1 mice. As shown in Figure 1a,
the cumulative survival was reduced in b2m° mice as com-
pared with b2m+/- and b2m+/+ littermates (n = 31 to 66 ani-
mals per group). The reduction in survival in b2m° mice
was associated with a higher frequency and earlier onset of
severe proteinuria than in controls (Figure 1b). To further
document the extent of renal disease exacerbation in b2m°
mice, we scored stained renal sections (Figure 1c, d), which
showed an increased composite kidney biopsy index as well
as its components, glomerular activity and chronicity
scores, in female (unpublished data) and in male mice that
normally do not develop severe nephritis (Figure 1c). Vas-
cular lesion scores, including thrombotic microangiopathy
lesions, were not different among the three groups of mice
(unpublished data). Thus, inflammation and fibrotic dis-
ease, but not vascular disease, were accelerated in b2m°
mice.
b2m deficiency in BWF1 mice reduces total serum IgG,
but not IgM levels
Hypergammaglobulinemia is a feature of lupus. Thus, we
expected to find increased IgG in b2m° BWF1 mice that
experienced severe disease (Figure 1). However, b2m°
BWF1 mice had reduced serum levels of total IgG and
IgG2a as compared to b2m+/- and b2m+/+ littermates
(Figure 2a, b). Serum levels of total IgM (Figure 2c), how-
ever, were unaffected in b2m° mice. Thus, b2m° BWF1
mice experience disease exacerbation at an age when they
have low levels of total IgG and the IgG isotype of most
pathogenic autoantibodies, IgG2a [32].
b2m° BWF1 mice have enhanced anti-DNA antibody and
RF levels
Exacerbation of lupus, despite reduced IgG levels, in
b2m° mice raised a possibility that they develop disease
via a mechanism that is not dependent on IgG autoanti-
bodies. However, the frequency of positivity and serum
levels of IgG anti-dsDNA antibody were higher in b2m°
mice than in control mice (Figure 3a, b). Male BWF1
mice, which normally do not develop autoantibodies in
early life, had a marked increase in the prevalence of
anti-dsDNA antibody (0% in b2m+/+ vs 31% in b2m°
mice at 4 months of age; P = 0.01; Fisher’s exact test
(data not shown)). Thus, anti-DNA B cells must be pro-
foundly activated in b2m° mice from early life.
The frequency of positive RF and its levels in b2m°
BWF1 mice showed a bimodal pattern, that is, its fre-
quency and levels were lower than in b2m sufficient
mice in early life, but the frequency and levels increased
in b2m° mice to surpass the levels in the control litter-
mates as the animals aged (Figure 3a, b). We surmise
that the early decrease in RF in b2m° mice may be
related to the absence of FcRn, whereas the increased
RF in later life may be due to increased activation of
RF-producing B cells.
CD1d deficiency increases serum IgG and RF in BWF1
mice
The effects of b2m on lupus described above could be
mediated by a variety of cell surface molecules, such as
FcRn, MHC class I, Qa1 and CD1d, which require b2m
for their optimal surface expression [10,11]. While reduced
total IgG levels in the early life of b2m° mice (Figure 2)
can be explained by the absence of FcRn, the disease
exacerbation in b2m° BWF1 mice cannot be explained by
FcRn-deficiency. Hence, we examined the effect of CD1d-
deficiency on total IgG and autoantibody levels in the
CD1d° BWF1 mice that we have generated [8]. We found
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Figure 1 b2 microglobulin (b2m) deficiency reduces survival and accelerates lupus nephritis in BWF1 mice. We monitored 33 b2m-/-
(b2m°) (18 female and 15 male, open circles), 66 b2m+/- (30 female and 36 male, triangles) and 31 b2m+/+ (18 female and 13 male, closed
circles) littermates for the development of lupus. (a) Cumulative percent survival in b2m° BWF1 mice was compared with control b2m+/- and
b2m+/+ littermate mice (*P <0.01 to 0.05, log rank test). (b) Cumulative percent mice with severe proteinuria (≥300 mg/dl protein on two
consecutive occasions) was increased in b2m° mice compared to control littermates (*P = 0.02 to 0.05, Fisher’s exact test). Differences were more
pronounced (P <0.01) when b2m° mice were compared with all controls (b2m+/- plus b2m+/+) mice. (c) Renal histological changes are expressed
as the mean ± standard error of the composite kidney biopsy index and its components, glomerular activity and chronicity scores. Results from
a representative experiment are shown (*P <0.05, b2m° vs control groups; n = 6 to 8 male 10-month-old mice per group, Student’s t-test). (d)
Representative kidney sections from these mice show severe kidney lesions with fibrosis (note increased aniline blue staining) in the glomeruli
(glomerulosclerosis, GS), periglomerular region (fibrous crescent, FC) and interstitium (IF), interstitial inflammation, and large segmental lesions
(SL) in b2m° mice, whereas the b2m+ mice showed relatively less advanced lesions with increased glomerular cellularity (GC) and typical
immune deposits (ID, see pink-colored deposits), but minimal or no GS or IF. PAS, periodic acid Schiff.
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that unlike b2m° BWF1 mice that had lower serum levels
of IgG than control littermates (Figure 2), CD1d° BWF1
mice had significantly increased total serum IgG levels
compared with CD1d+ littermates (Figure 4a). Serum RF,
which is not normally detected in high titers in BWF1
mice, was also increased in the CD1d° mice compared
with CD1d+ littermates (Figure 4b). Serum IgG anti-
dsDNA antibody levels and lupus nephritis were also ele-
vated in CD1d° BWF1 mice compared to controls (data
not shown), as also reported previously [8]. Thus, the lack
of a regulatory role of CD1d may explain, at least in part,
the acceleration of lupus disease in b2m° BWF1 mice.
Anti-CL antibody levels are reduced in b2m° BWF1 mice
Preliminary analyses of autoantibodies using ELISA and
western blot showed that a variety of antibodies against
cellular and nuclear antigens were higher in b2m° BWF1
mice than in control littermates (data not shown). Surpris-
ingly, however, no b2m° BWF1 mice had anti-CL antibo-
dies above the cutoff level (mean + 4 (SD) OD in normal
BALB/c mice). Subsequent analysis in a large cohort of
mice showed that 6 to 10% of b2m° BWF1 mice compared
to 36 to 39% of control littermates were positive for IgG
anti-CL antibodies at different ages (P <0.01, Fisher’s exact
test). Levels of serum anti-phospholipid antibody were sig-
nificantly lower in b2m° BWF1 mice than in control litter-
mates (Figure 5a, b). These data suggest a contribution of
b2m in the production of anti-CL antibodies in BWF1
mice.
CD1d plays a role in the production of anti-CL antibody
CD1d can bind phospholipid antigens [19,20] and activate
T-cells [21,22]. We reasoned that the absence of such
CD1d-restricted self-phospholipid-reactive T-cells might
result in the decreased production of anti-phospholipid
antibody in b2m° and CD1d° BWF1 mice. Indeed, serum
IgG anti-phospholipid antibody levels were reduced in
CD1d° BWF1 mice compared with CD1d+ littermates
(Figure 5c).
CD1d-restricted T cells comprise glycolipid-reactive
iNKT cells that express the invariant TCR Va14Ja18 and
other NKT cells that do not express the invariant TCR. To
determine the effect of iNKT cells on various autoantibo-
dies, we cultured BWF1 spleen cells with glycolipid aGal-
Cer. We found that while IgG anti-DNA antibody levels
were reduced in the presence of aGalCer, IgG anti-CL
antibody levels were unaffected (Figure 6a).
To further evaluate the differential effects of iNKT
cells on anti-DNA versus anti-CL antibodies in vivo, we
reconstituted BALB/c SCID mice with purified B cells
Figure 2 Serum immunoglobulin (Ig) levels in b2 microgloblin-
deficient (b2m°) BWF1 mice: reduced polyclonal total IgG, but
not IgM. b2m+/+ (n = 18 to 22 female and 12 male, closed circles),
b2m+/- (n = 30 to 35 female and 28 to 35 male, triangles) and b2m°
(n = 11 to 16 female and 10 to 16 male, open circles) mice were
bled and sera tested for total IgG, IgG2a and IgM. Results are
expressed as the mean ± standard error. (a, b) Serum levels of total
IgG and IgG2a isotype were lower in b2m° mice than in control
animals (*P <0.05, **P <0.01 to <0.001; Student’s t-test). (c) Serum
levels of total IgM were higher in b2m° than in b2m+/+ mice (*P
<0.05, Student’s t-test).
Figure 3 Serum anti-dsDNA autoantibodies and rheumatoid
factor (RF) are increased in b2 microglobulin-deficient (b2m°)
BWF1 mice. b2m+/+ (n = 18 female and 12 male, closed circles),
b2m+/- (n = 30 female and 28 male, triangles), and b2m-/- (n = 11
female and 10 male, open circles) mice were bled and serum
samples tested for IgG anti-dsDNA antibody and RF. (a) Results are
expressed as the percent of mice with autoantibodies, using a
cutoff level of the mean + 4 SD optical density (OD) value in sera
from six normal age-matched BALB/c mice. Results pooled from
male and female mice are shown (*P <0.05, **P <0.01; Fisher’s exact
test). (b) Results of autoantibodies are shown as the mean ±
standard error of log U/ml in male and female mice separately
(*P <0.01 to 0.05, **P <0.001, Student’s t-test).
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from iNKT cell-deficient Ja18° BALB/c mice (to avoid
any contamination with iNKT cells or iNKT cell-
exposed B cells). These mice were then implanted with
T-cells from Va14Tg BALB/c mice that have >50%
T-cells as iNKT cells or with T-cells from Ja18° BALB/c
mice that have no iNKT cells. As shown in Figure 6b,
spleen cells from SCID mice implanted with iNKT cells
produced lower levels of IgG anti-DNA antibody levels
than spleen cells from SCID mice implanted with Ja18°
T-cells. However, anti-CL antibody levels were unaf-
fected by the presence or absence of iNKT cells. These
data suggest that while glycolipid-reactive iNKT cells
suppress anti-DNA antibody production, they do not
affect the development of anti-CL antibodies.
Discussion
Here, we show that BWF1 mice rendered deficient in b2m
exhibit markedly increased renal disease with reduced
survival, despite reduced serum IgG and IgG2a levels in
early life. IgG anti-DNA antibody and RF are increased,
but anti-phospholipid antibody levels are reduced in b2m°
mice. All, but one, of these effects of b2m-deficiency may
be explained, at least in part, by the absence of CD1d, with
which b2m non-covalently associates, as CD1d° BWF1
mice also have accelerated nephritis, increased IgG anti-
DNA antibody and RF, but reduced anti-phospholipid
antibody levels. However, unlike b2m° mice, which have
reduced serum IgG, CD1d° mice have increased serum
IgG. Thus, b2m-deficiency may affect lupus via at least
three possible mechanisms: 1) the effects of FcRn on IgG
catabolism; 2) the immunoregulatory role of CD1d, and 3)
the ability of CD1d to bind phospholipids to induce anti-
phospholipid autoimmunity.
IgG antibodies comprise the major isotype responsible
for humoral immunity and the pathological effectors of
lupus [32]. The FcRn protects IgG from catabolism by
diverting it from a degradative fate in lysosomes [17,18].
The IgG molecules of FcRn-deficient mice have an abnor-
mally short half-life [17,18]. Because a functional FcRn
Figure 4 Serum total immunoglobulin G (IgG) and rheumatoid
factor (RF) are increased in CD1d-deficient (CD1d°) BWF1 mice.
CD1d° BWF1 mice and control littermates (CD1d+/+ or CD1d+/-,
designated as CD1d+) were bled and serum samples tested for total
IgG and RF levels. (a) Eight-month-old CD1d+ (n = 7) and CD1d°
(n = 13) mice (*P = 0.04). (b) CD1d+ (n = 8) and CD1d° (n = 15)
mice (*P <0.01 and **P = 0.03 to 0.06). The negative control mean
± SD value in six normal BALB/c mice was 28.2 ± 8.6 U/ml for RF.
Results are expressed as the mean ± standard error of the values.
Figure 5 Serum anti-cardiolipin (anti-CL) antibodies are
decreased in b2 microglobulin-deficient (b2m°) and CD1d-
deficient (CD1d°) BWF1 mice. (a-c) b2m° or CD1d° BWF1 mice
and control littermates (b2m+/+ or b2m+/-, designated as b2m+; and
CD1d+/+ or CD1d+/-, designated as CD1d+) were bled and serum
samples tested for serum immunoglobulin G (IgG) anti-CL
antibodies: (a) 4-month-old b2m+ (n = 88) and b2m° (n = 32); (b) 6-
to 8-month-old b2m+ (n = 75) and b2m° (n = 14); (c) 7- to 8-
month-old CD1d+ (n = 57) and CD1d° (n = 26) mice. Each symbol
represents a single mouse, and horizontal bars represent the mean
U/ml for the group. The negative control mean ± SD values for
anti-CL antibody in six normal BALB/c mice was 15.1 ± 5.2 U/ml.
*P <0.01, Student’s t-test.
Figure 6 Activated invariant natural killer T (iNKT) cells reduce
anti-DNA antibodies, but not anti-cardiolipin (anti-CL)
antibodies. (a) In vitro studies. Spleen cells harvested from
5-month-old BWF1 mice were cultured with aGalCer for 5 days, and
supernatants tested for immunoglobulin G (IgG) anti-DNA and anti-
CL antibodies, shown as the mean ± SD optical density (OD);
*P <0.05 to 0.01, n = 5. Results represent two similar experiments.
(b) In vivo studies. BALB/c SCID mice (4-month-old) were
reconstituted with purified B-cells from iNKT cell-deficient Ja18°
BALB/c mice, and injected with lipopolysaccharide and aGalCer, as
described in Methods. These mice were then implanted with T-cells
from Va14Tg BALB/c mice or with T-cells from Ja18° BALB/c mice.
Four days after the reconstitution, spleen cells were harvested and
cultured without any further stimulation for 6 days. Culture
supernatants were tested for IgG anti-DNA and anti-CL antibodies.
Results represent two independent experiments, each using three
mice per group. *P <0.05.
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molecule is dependent upon dimerization with b2m, b2m°
mice also have reduced serum IgG [15,18]. Consistently,
b2m° BWF1 mice have reduced serum IgG in pre- and
early disease stages (Figure 2), but not in 8-month-old
female (Figure 2) and male and female mice with terminal
disease (data not shown). This lack of decrease in total
serum IgG in older b2m° BWF1 mice could be due to a
relative increase in IgG isotypes that bind weakly to FcRn
and thus are less affected by the absence of FcRn. How-
ever, differences in the binding affinity of mouse FcRn for
different mouse IgG isotypes are relatively small, with
equilibrium dissociation constants (KD) of 0.42, 0.5 and
0.75 for IgG2a, IgG2b and IgG1, respectively [33]. Mam-
malian FcRn is specific for IgG and does not bind IgA,
IgM and IgE. Consistently, serum IgM levels were unaf-
fected in b2m° BWF1 mice. FcRn found on macrophages
and dendritic cells can also facilitate the presentation of
immune complexed antigens to T-cells [34,35]. Thus, the
reduced antigen presentation and T-cell activation owing
to FcRn-deficiency might contribute to the reduced IgG
antibodies in b2m° mice.
The above effects of FcRn, however, do not explain
lupus exacerbation in b2m° mice, which was severe
enough to cause reduced survival (Figure 1a). Arguing
against the role of FcRn in mediating the protective effect
of b2m in lupus, the direct deficiency of FcRn did not
affect survival in lupus-prone BXSB.Yaa mice [36]. Impor-
tantly, the effect of FcRn cannot explain an increase in
anti-DNA antibodies in b2m° mice (Figure 3). Moreover,
serum IgG increased as b2m° mice aged (Figure 2), despite
the lack of FcRn that protects IgG against degradation.
Serum levels of IgG2a that binds most avidly to mouse
FcRn were also increased as the b2m° animals developed
disease. Thus, a profound activation of autoreactive B-cells
must occur in b2m° mice to have increased levels of circu-
lating autoantibodies.
We have previously reported that tolerance in anti-
dsDNA B-cells can be broken by autoreactive T-cells in
non-autoimmune mice [5]. Such breakdown of tolerance
is curtailed, however, by the emergence of T-cells that
can inhibit autoantibody production [5]. These inhibi-
tory T-cells are mostly CD8+ T-cells that suppress auto-
antibody production via transforming growth factor b
(TGFb) [5,28] or B-cell ablation [6]. The latter, cyto-
toxic, CD8+ T-cells recognize MHC class I-restricted
peptides [6]. Expression of MHC class 1b molecule, Qa-
1, by activated B-cells can also mediate CD8+ T-cell
suppression of immune responses [37,38]. In fact, the
genetic disruption of the inhibitory interaction between
CD8+ T-cells and their target Qa-1+ T-cells results in
the development of autoantibodies and nephritis [39].
Thus, both classical and non-classical MHC class I
molecules might contribute to disease protection in
b2m-intact BWF1 mice.
In resonance with the above, the deficiency of MHC
class I molecules H-2K and H-2D, of Tap1, which is
required for the loading of processed peptides onto
H-2K/D, or of CD8a, reduces survival in BXSB.Yaa
mice [36]. However, the acceleration in mortality in
BXSB.Yaa mice rendered deficient in H-2K/D, Tap1, or
CD8a was not as profound as that observed in b2m°
BXSB.Yaa mice [36], suggesting that more than one
mechanism likely accounts for the protective effect of
b2m in lupus.
Not all studies favor a protective role of MHC class
Ia/b-restricted CD8+ T-cells in lupus disease. For exam-
ple, CD8-deficiency in NZB mice has been found to
have no effect on anti-DNA antibody production [40].
The adoptive transfer of splenic CD8+ T-cells into b2m°
BWF1 mice also had no effect on disease in our preli-
minary study (data not shown). Thus, different mechan-
isms may account for the protective effect of b2m in
different lupus-prone strains.
The disease-protective effects of b2m-dependent MHC
class I proteins in BXSB.Yaa mice could be attributed to
the additive functions of CD8+ T-cells and IL-15 [36]. IL-
15 also regulates the homeostasis and maturation of
NKT-cells [41] that are restricted by CD1d, another
b2m-associated molecule. Ample evidence suggests a reg-
ulatory role of CD1d-restricted T-cells in lupus and
related diseases [8,24,31,42,43]. In fact, CD1d deficiency
exacerbates nephritis and reduces survival in the hydro-
carbon oil-induced and BWF1 models of lupus and der-
matitis in MRL-lpr mice [8,24,42], although it has no
effect on nephritis in MRL-lpr mice, or on survival in
BXSB.Yaa mice [16,36,42]. CD1d-deficiency increases the
production of many autoantibodies including anti-DNA,
anti-OJ and anti-ribosomal P antibodies [8,24], and RF
(Figure 4). Recent evidence also indicates a direct regula-
tion of autoreactive B-cells by CD1d-reactive NKT cells
[31,44]. Thus, it is reasonable to suggest that the protec-
tive effects of b2m against humoral autoimmunity and
nephritis may be mediated, at least in part, via the regula-
tory effect of CD1d-reactive NKT-cells.
CD1d-reactive T-cells comprise heterogeneous popula-
tions of cells [45,46]. In a previous study, adoptive transfer
of CD1d-reactive single positive T-cells induced a lupus-
like disease in nude mice, whereas CD1d-reactive TCRab
+CD4-CD8- T-cells prevented the induction of autoimmu-
nity [47]. Thus, some CD1d-reactive T-cells might protect
against autoimmunity, whereas others might enhance
autoimmune disease. Such diverse CD1d-reactive T-cells
are likely to recognize different antigens and exert differ-
ent functions.
Some CD1d-restricted T-cells can recognize phospho-
lipid antigens bound to CD1d [21,22]. Function of these
phospholipid-reactive T-cells is not understood. We
demonstrated that serum anti-phospholipid antibody
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levels are reduced in b2m° and CD1d° mice (Figure 5).
These data for the first time raise a possibility that
CD1d presentation of self-phospholipids might induce
anti-phospholipid autoantibodies, although further stu-
dies are needed to directly test this idea.
The reduction in anti-CL antibody levels in CD1d°
mice was not due to a lack of anti-CL B-cell repertoire,
as addition of lipopolysaccharide (LPS) to spleen cell
cultures increased the levels of IgG anti-CL antibodies
in these mice (Additional file 1, Figure S1). Thus, anti-
CL B-cells exist in CD1d° mice, but they require CD1d
for their activation in vivo.
We have recently reported that CD1d-restricted iNKT
cells that respond to glycolipid aGalCer suppress the
production of anti-DNA antibody and RF [31,48]. We
asked whether such iNKT-cells promote anti-CL anti-
body production. In contrast to the effects of aGalCer on
anti-DNA antibodies, anti-CL antibody levels were unaf-
fected in BWF1 spleen cell cultures containing aGalCer
(Figure 6a). Consistently, iNKT cells reduced IgG anti-
DNA antibodies in SCID mice reconstituted with B-cells
and iNKT-cells, but did not affect anti-CL antibody levels
(Figure 6b). Thus, glycolipid-reactive type 1 iNKT-cells
suppress the production of autoantibodies against non-
phospholipid autoantigens, whereas non-iNKT cells, also
called type 2 CD1d-restricted T-cells, might promote
anti-CL antibody production.
Although this study used N10-N14 backcrossed mice
that are expected to carry ≤0.1% genes from the 129/B6
b2m° or CD1d° founders, there remains the possibility that
our results reflect the alteration of linked gene(s) during
the backcross of the mutated b2m or CD1d 129 locus
onto the lupus genetic backgrounds. Genotype analyses of
our final backcrossed mice using simple sequence repeat
markers, however, do not suggest a replacement with 129/
B6 genes at any of the loci tested (data not shown). More-
over, differential regulation of different autoantibodies,
increased anti-DNA and RF, and decreased anti-CL anti-
body, further suggests that the observed effects are not
simply due to introgression of another gene that may have
caused non-specific B-cell activation. Furthermore, similar
data were obtained in more than one knockout strain,
namely b2m° and CD1d° BWF1, arguing against the possi-
bility that other lupus-susceptibility genes are responsible
for our observations.
Conclusions
Different MHC class I-related molecules associated with
b2m play distinct roles in the development of different
autoantibodies (Figure 7). A clear understanding of these
roles may have implications for the development of novel
therapies for the treatment of complex multi-system
lupus disease. For example, inhibition or neutralization of
FcRn may increase IgG catabolism [17], thus reducing
the levels of pathogenic IgG autoantibodies, and the acti-
vation of regulatory CD8+ or iNKT-cells may protect
against autoimmunity. Patients with SLE and related dis-
eases have reduced numbers and/or functions of CD1d-
reactive T-cells [9,49-51], so the boosting of CD1d-reac-
tive T-cells should be explored as a therapeutic strategy
in SLE. In fact, treatment with rituximab restores the
numbers and functions of CD1d-reactive T-cells to near-
normal levels in patients with SLE [50]. There is a need
for caution, however, as some CD1d-restricted T-cells
might activate anti-phospholipid B cells and might
induce or worsen anti-phospholipid syndrome, which
manifests with vascular thrombosis and loss of pregnancy
[52]. Further studies are needed to dissect the roles of
CD1d-restricted glycolipid-reactive vs phospholipid-reac-
tive T-cells in conferring the protective vs pathogenic
roles in SLE.
Additional material
Additional file 1: Table S1: A table showing the renal biopsy
scoring system. Scales for scores, indices and individual components.
Figure S1: A figure showing that the reduction in anti-cardiolipin
antibody levels in CD1d° mice is not due to a lack of anti-cardiolipin B
cell repertoire in these mice. Anti-cardiolipin antibody levels in cultured
supernatants of spleen cells stimulated with lipopolysaccharide (LPS)
from wild-type (WT) and CD1d-deficient (CD1d°) mice.
Figure 7 Distinct roles of different b2 microglobulin (b2m)-
associated glycoproteins in the regulation of humoral
autoimmunity. The findings in this report and previous studies
suggest that b2m may affect lupus-like autoimmunity via at least six
possible mechanisms: 1) neonatal Fc receptor (FcRn) effects on
immunoglobulin G (IgG) catabolism [17,18] (Figure 2); 2) Qa-1-
restricted CD8+ regulatory or suppressor T-cells that can suppress
autoimmunity [39]; 3) major histocompatability complex (MHC) class
I-restricted CD8+ Ti cells (inhibitory T-cells) that suppress
autoantibody production via production of transforming growth
factor b [5,28]; 4) MHC class I-restricted CD8+ cytotoxic T
lymphocytes (CTL) that can ablate autoreactive B-cells [6]; 5)
protective role of CD1d-restricted glycolipid (GL)-reactive invariant
natural killer T (iNKT)-cells in autoimmunity [8,24,31,42,44] (Figures 4
and 6a); and 6) the ability of CD1d to bind phospholipid (PL)
antigens to induce anti-phospholipid autoimmunity (Figure 5). RF,
rheumatoid factor; APC, antigen presenting cell.
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